MMRGlobal, Inc. (fka MMRF)

[sakata7]

MMR is excited about Celgene’ s recent announcement pertaining to their progress with “follicular lymphoma” using the product “lenalidomide” which is also a subject of MMR’s licensing agreement with Celgene;

CELGENE has announced plans to complete enrollment of its phase III study of lenalidomide plus rituximab in patients with previously untreated disease in the second half of 2014;

http://www.sec.gov/Archives/edgar/data/1285701/000113626111000182/exh10-32.htm

http://ir.celgene.com/releasedetail.cfm?releaseid=866799

"In follicular lymphoma, the company expects to complete enrollment of RELEVANCE, its phase III study of lenalidomide plus rituximab compared with rituximab plus chemotherapy in patients with previously untreated disease in the second half of 2014."